Plain-English translation of NCT06992232 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new approach to treat advanced prostate cancer that has spread to other areas of the body. Men in the trial will receive hormone-blocking medications (including enzalutamide, apalutamide, darolutamide, or rezvilutamide) for 2 years. Some participants will also receive either radiation therapy or surgery to remove the primary tumor and affected lymph nodes, while others will receive the medication alone. Researchers want to see if adding local treatment (radiation or surgery) improves outcomes for patients with this advanced disease.
Current treatments for advanced prostate cancer focus mainly on hormone therapy, but researchers believe that adding radiation or surgery to target the main tumor might help patients live longer and control their disease better. This trial aims to find out which approach works best.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take hormone-blocking medication for 2 years. You will be randomly assigned to either receive the medication alone or receive the medication plus either radiation therapy or surgery to treat your primary tumor. If assigned to radiation, you would receive treatments over several weeks. If assigned to surgery, you would have a robot-assisted procedure to remove your prostate and nearby lymph nodes. Throughout the trial, you will have regular visits to monitor your health, blood tests, and imaging scans.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China